Ixtlan Bioscience

Ixtlan Bioscience is an Israel-based private biotech company developing psilocybin micro-dosing therapies for neurodegenerative and other brain pathologies. The company has described a proprietary program called the Ixtlan AD Kit, an at-home treatment approach combining encapsulated psilocybin micro-doses, a digital web application, cognitive exercises, and metabolite monitoring. Its primary focus has been Alzheimer's disease and related dementias, with broader references to stroke, multiple sclerosis, and traumatic brain injury. Publicly available information indicates an early-stage company centered on psychedelic medicine for neurological and cognitive disorders, with limited evidence of disclosed clinical-stage assets.